Biotechnology

A market set to triple, driven by gene-level therapies, promises a revolution for children with rare epilepsies. But can our systems deliver this hope?

Cytovance Biologics' new cell line service boasts top-tier yields. This strategic shift toward a 'one-stop-shop' model could redefine speed and cost in biopharma.

NBA legend Shaquille O'Neal's campaign for Zepbound spotlights a silent health epidemic, but the drug's high cost and the ethics of celebrity ads loom large.

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

An expanded partnership between GENESIS Pharma and Alnylam is set to bring revolutionary RNAi therapies to the Nordics. But can it navigate the region's tough economic hurdles?

New clinical data suggests Cullinan Therapeutics' cancer-fighting tech could offer durable, treatment-free remission for severe RA and lupus patients.

Organon's FDA nod for TOFIDENCE in critical care isn't just a clinical win. It's a calculated move to capture market share and challenge high-cost biologics.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

A landmark deal sees Novartis invest up to $1.4B in Orionis Biosciences' AI platform, aiming to turn the chance discovery of 'molecular glue' drugs into a science.

With $101M from top VCs, Ethyreal Bio emerges from stealth to target the root cause of both Graves' Disease and Thyroid Eye Disease with a single antibody.

As AI fatigue hits markets, one sector sees a real breakthrough. Taiwan's TFC is using AI to boost IVF success, offering new hope to infertile couples.

A new deal brings a breakthrough blood cancer therapy, Zemcelpro®, closer to Canada. But for patients with few options, the 2028 timeline is a stark reminder of the gap between innovation and access.

One in six people globally faces infertility, yet a pervasive stigma silences their struggle. A worldwide movement is now uniting millions to demand change.

A UK firm's regulatory milestone is more than just compliance; it's a strategic masterclass in building the resilient systems needed to fight food allergies.

Questex's Fierce Biotech is launching a UK event, but this is more than expansion. It’s a calculated bet on London's future as a biotech superpower.

As new drugs outpace manufacturing capacity, a French giant bets on local production in China to build the supply chains of tomorrow's therapies.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

Biotech firm Sensorion drops one gene therapy to fast-track another, aiming to cure GJB2-related hearing loss, the leading cause of genetic deafness.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

Mickey Mikitani shifts to Executive Chairman, installing a new CEO to navigate the high-stakes journey from visionary science to U.S. market reality.